References

Global epidemiology of NAFLD—meta-analytic assessment of prevalence, incidence, and outcomes

10.1002/hep.28431 · 2018 · External reference

Metabolic dysfunction-associated steatotic liver disease (MASLD): a State-of-the-art review

10.7570/jomes23052 · 2023 · External reference

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases

10.1002/hep.29367 · 2018 · External reference

Non-alcoholic fatty liver disease and the metabolic syndrome: an update

10.3748/wjg.14.185 · 2008 · External reference

Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study

10.3390/healthcare11192696 · 2023 · External reference

Fatty liver: a disease of the 21st century

2011 · External reference

Metabolic dysfunction-associated steatotic liver disease heterogeneity: need of subtyping

10.4291/wjgp.v15.i2.92791 · 2024 · External reference

Natural history of metabolic dysfunction-associated steatotic liver disease

10.1016/j.ejim.2023.11.005 · 2024 · External reference

Nonalcoholic fatty liver disease: evolving paradigms

10.3748/wjg.v23.i36.6571 · 2017 · External reference

Visceral adipose tissue accumulation differs according to ethnic background: results of the multicultural community health assessment trial (M-CHAT)

10.1093/ajcn/86.2.353 · 2007 · External reference

Metabolic dysfunction- associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study

10.1002/hep.32131 · 2022 · External reference

Waist circumference and waist-to-hip ratio as predictors of mortality in men and women

2015 · External reference

Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis

10.3350/cmh.2018.0034 · 2018 · External reference

Longitudinal assessment of visceral adiposity and risk of incident MASLD

2019 · External reference

Relationship between anthropometric measures and the risk of incident metabolic dysfunction-associated steatotic liver disease: a longitudinal study

10.1186/s12876-025-03780-8 · 2025 · External reference

Exploring biomarkers in nonalcoholic fatty liver disease among individuals with type 2 diabetes mellitus

10.1097/mcg.0000000000002079 · 2025 · External reference

Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group

10.1016/j.aohep.2025.101903 · 2025 · External reference

Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: an obesity medicine association (OMA) and expert joint perspective 2025

2025 · External reference

Diagnostic accuracy of FibroScan and factors affecting measurements

10.3390/diagnostics10110940 · 2020 · External reference

Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population

10.1186/s12944-024-02100-5 · 2024 · External reference

Obesity-induced hepatic steatosis is partly mediated by visceral fat accumulation in subjects with overweight/Obesity: a cross-sectional study

10.1159/000527595 · 2023 · External reference

Roles of immune dysregulation in MASLD

10.1016/j.biopha.2023.116069 · 2024 · External reference

Adipose tissue inflammation and metabolic dysfunction in obesity

10.1152/ajpcell.00379.2020 · 2021 · External reference

The immune landscape of visceral adipose tissue during obesity and aging

10.3389/fendo.2020.00267 · 2020 · External reference

Nonalcoholic fatty liver disease: the role of visceral adipose tissue

10.1002/cld.1183 · 2022 · External reference

Metabolic-dysfunction- associated steatotic liver disease: its pathophysiology, association with Atherosclerosis and cardiovascular Disease, and treatments

10.3390/ijms242015473 · 2023 · External reference

Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study

10.1186/s12933-025-02716-6 · 2025 · External reference

Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease

10.3390/ijms15046184 · 2014 · External reference

Genetic and environmental factors contributing to visceral adiposity in Asian populations

10.3803/enm.2020.772 · 2020 · External reference

Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis

2019 · External reference

The visceral adiposity index in non-alcoholic fatty liver disease and Liver Fibrosis-systematic review and Meta-analysis

10.3390/biomedicines9121890 · 2021 · External reference

Visceral adipose tissue quality was associated with nonalcoholic fatty liverdisease, independent of its quantity

10.1016/j.numecd.2022.01.009 · 2022 · External reference

A indicator of visceral adipose dysfunction to evaluate metabolic health in adult Chinese

10.1038/srep38214 · 2016 · External reference

Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease

10.5402/2011/592404 · 2011 · External reference

The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis

10.1016/j.metabol.2020.154455 · 2021 · External reference